Unicycive Therapeutics Reports Q3 GAAP EPS of -$0.25, Beating Estimates
Unicycive Therapeutics (UNCY) reported third-quarter GAAP earnings per share of -$0.25, surpassing analyst expectations by $0.10. The company's financial position remains stable with $59 million in cash, cash equivalents, and marketable securities as of September 30, 2026. Management indicated that the current capital reserves provide a sufficient runway extending beyond 2027. This liquidity is expected to cover ongoing operations and the potential commercial launch costs for OLC.

Topics: cash runway earnings beat financial results
Read the full article at Seeking Alpha
Part of the story Neumora Therapeutics Reports Q3 GAAP EPS of -$0.18, Exceeding Estimates (3 articles)